Astellas to work with Adaptimmune to develop 'off the shelf'...

Astellas is to work with UK biotech Adaptimmune Therapeutics to develop allogeneic ‘off-the-shelf’ T-cell therapies for cancer.

FDA backs Astellas/Seattle Genetics bladder cancer drug

The FDA has quickly okayed Astellas and Seattle Genetics’ advanced bladder cancer drug enfortumab vedotin, one of the stars of this year’s ASCO conference that was considered an almost dead

Xtandi catches up with Erleada in castration-sensitive prost...

Patient-partnered drug discovery: vision or reality?

pharmaphorum’s Paul Tunnah talks to Anthony Yanni, newly appointed senior vice president & global head of patient centricity, Astellas, about why partnering with patients is the corners

Astellas buys gene therapy company for $3bn

Astellas has announced it will be acquiring gene therapy specialists Audentes Therapeutics for a total equity value of approximately $3 billion, adding a new focus area to its drug discovery eff

AZ preps for US filing of kidney disease anaemia drug

AstraZeneca is gearing up for a US filing for its roxadustat, a potential drug for patients with anaemia from chronic kidney disease (CKD), after supportive phase 3 results.